Breaking News From Pharma & Bio Ingredients
Genitope Continues Non-Hodgkin's Lymphoma Trial
Posted on 2006-07-28 08:54:00
Genitope Corporation today announced that its independent Data Safety Monitoring Board (DSMB) reviewed the second planned interim analysis of data for efficacy in its pivotal Phase 3 clinical trial for treatment of follicular non-Hodgkin's Lymphoma (fNHL) and recommended that the trial continue as planned. The clinical trial will be completed by December 2007.
This trial evaluates the safety and efficacy of the company's lead product candidate, MyVax personalized immunotherapy, in patients with previously untreated fNHL. The trial compares patients treated with MyVax personalized immunotherapy to patients treated with a nonspecific immunotherapy control.
Subscribe via RSS
